臨床婦人科産科67巻11号

2013年11月発行

今月の臨床 進行婦人科がんの集学的治療

卵巣がん

1．進行卵巣がんの治療戦略―初回手術・術前化学療法どちらを選ぶか

著者： 遠藤大介¹ 渡利英道¹ 櫻木範明¹

所属機関： ¹北海道大学医学部産婦人科

ページ範囲：P.1146 - P.1153

文献概要

●進行卵巣がんの予後因子として初回手術後の残存腫瘍径が重要であり，最大限の腫瘍減量のために術前化学療法が考慮される．

●術前化学療法後の腫瘍減量手術が予後の改善に寄与するかどうかに関して，新たな知見が得られてきている．

●いくつかの臨床試験の結果から，術前化学療法＋腫瘍減量手術が標準治療の1つの選択肢として容認されていく可能性がある．

参考文献

1） Matsuda T, Marugame T, Kamo K, et al : The Japan Cancer Surveilance Research Group. Cancer Incidence and Incidence Rates in Japan in 2005 : Based on Data from 12 Population-based Cancer Registries in the Monitoring of Cancer Incidence in Japan（MCIJ） Project. Japanese Journal of Clinical Oncology 41 : 139─147, 2011

2） 国立がん研究センターがん対策情報センター．がん情報サービス．がんの統計12, http://ganjoho.jp/public/statistics/backnumber/2012_jp.html

3） 平成22年人口動態統計　厚生労働省大臣官房統計情報部編

4） 婦人科腫瘍委員会報告．第50回治療年報 : 2002年に治療した卵巣癌の5年治療成績について．日産婦誌63 : 1817─1880，2011

5） Hogberg T, Carstensen J, Simonsen E, et al : Treatment results and prognostic factors in a population-based study of epithelial ovarian cancer. Gynecol Oncol 48 : 38─49, 1993

6） Swenerton KD, Hislop TG, Spinelli J, et al : Ovarian carcinoma : a multivariate analysis of prognostic factors. Obstet Gynecol 65 : 264─270, 1985

7） 日本婦人科腫瘍学会 : 卵巣がん治療ガイドライン2010年版，金原出版，2010

8） Bertelsen K, et al : Tumor reduction surgery and long-term survival in advanced ovarian cancer : a DACOVA study. Gynecol Oncol 38 : 203─209, 1990

9） Hacker NF, Berek JS, Lagasse LD, et al : Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 61 : 413─420, 1983

10） Makar AP, Baekelandt M, Tropé CG, et al : The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol 56 : 175─180, 1995

11） 遠藤大介，渡利英道，他 : 上皮性卵巣癌の予後因子に関する臨床病理学的検討．北海道産科婦人科学会雑誌56 : 43─48，2012

12） Bertelsen K, et al : Tumor reduction surgery and long-term survival in advanced ovarian cancer : a DACOVA study. Gynecol Oncol 38 : 203─209, 1990

13） Delgado G, Oram DH, Petrilli ES : Stage III epithelial ovarian cancer : the role of maximal surgical reduction. Gynecol Oncol 18 : 293─298, 1984

14） Neijt JP, ten Bokkel Huinink WW, van der Burg ME, et al : Randomized trial comparing two combination chemotherapy regimens（CHAP-5 v CP）in advanced ovarian carcinoma. J Clin Oncol 5 : 1157─1168, 1987

15） Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al : The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol 103 : 1083─1090, 2006

16） Mourton SM, Temple LK, Abu-Rustum NR, et al : Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol 99 : 608─614, 2005

17） Bristow RE, Peiretti M, Zanagnolo V, et al : Transverse colectomy in ovarian cancer surgical cytoreduction : operative technique and clinical outcome. Gynecol Oncol 109 : 364─369, 2008

18） Juretzka MM, Barakat RR : Pelvic cytoreduction with rectosigmoid resection. Gynecol Oncol 104 : 40─44, 2007

19） Dietrich CS, DeSimone CP, Modesitt SC, et al : Primary appendiceal cancer : gynecologic manifestations and treatment options. Gynecol Oncol 104 : 602─606, 2007

20） Ayhan A, Gultekin M, Taskiran C, et al : Routine appendectomy in epithelial ovarian carcinoma : is it necessary? Obstet Gynecol 105 : 719─724, 2005

21） Dowdy SC, Loewen RT, Aletti G, et al : Assessment of outcomes and morbidity following diaphragmatic peritonectomy for women with ovarian carcinoma. Gynecol Oncol 109 : 303─307, 2008

22） Fanfani F, Fagotti A, Gallotta V : Upper abdominal surgery in advanced and recurrent ovarian cancer : role of diaphragmatic surgery. Gynecol Oncol 116 : 497─501, 2010

23） Eisenkop SM, Spirtos NM, Lin WC : Splenectomy in the context of primary cytoreductive operations for advanced epithelial ovarian cancer. Gynecol Oncol 100 : 344─348, 2006

24） Panici PB, Maggioni A, Hacker N, et al : Systematic aortic and pelvic lymphadenoctomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer : a randomized clinical trial. J Natl Cancer Inst 97 : 560─566, 2005

25） du Bois A, Reuss A, Harter P, et al : Potential role of lymphadenectomy in advanced ovarian cancer : acombined exploratory analysis of three prospectively randomized phase III multicenter trials. JCO 28 : 1733─1739, 2010

26） Vergote I, Trope CG, Amant F, et al : Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363 : 943─953, 2010

27） Kuhn W, Rutke S, Spathe K, et al : Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patienst with poor prognosis in International Federation of Gynecology and Obstetrics stage IIIc ovarian carcinoma. Cancer 92 : 2585─2591, 2001

28） Lee SJ, Kim BG, Lee JW, et al : Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery. J Obstet Gynaecol Res 32 : 99─106, 2006

29） Hegazy MA, Hegazi RA, Elshafei MA, et al : Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma. World J Surg Oncol 3 : 57, 2005

30） Giannopoulos T, Butler-Manuel S, Taylor A, et al : Clinical outcomes of neoadjuvant chemotherapy and primary debulking surgery in advanced ovarian carcinoma. Eur J Gynaecol Oncol 27 : 25─28, 2006

31） Chan YM, Ng TY, Ngan HY, et al : Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer : a prospective longitudinal study. Gynecol Oncol 88 : 9─16, 2003

32） van der Burg ME, van Lent M, Buyse M, et al : The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 332 : 629─634, 1995

33） Rose PG, Nerenstone S, Brady MF, et al : Gynecologic Oncology Group. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 351 : 2489─2497, 2004

34） Ozols RF, Bundy BN, Greer BE et, al : Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer : a Gynecologic Oncology Group study. J Clin Oncol 21 : 3194─3200, 2003

35） Vasey PA, Jayson GC, Gordon A, et al : Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96 : 1682─1691, 2004

36） Katsumata N, Yasuda M, Takahashi F, et al : Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer : a phase 3, open-label, randomised controlled trial. Lancet 374 : 1331─1338, 2009

37） Bristow RE, Chi DS : Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer : a meta-analysis. Gynecol Oncol 103 : 1070─1076, 2006

38） Kang S, Nam BH : Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies. Ann Surg Oncol 16 : 2315─2320, 2009

39） Sean Kehoe, Jane Hook, Matthew Nankivell, et al : CHORUS（Chemotherapy or Upfront Surgery）. Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer : Results from the MRC CHORUS trial. J Clin Oncol 31（suppl : abstr 5500）, 2013

40） Onda T, Matsumoto K, Shibata T, et al : Phase III trial of upfront debulking surgery versus Neoadjuvant Chemotherapy for Stage III／IV Ovarian, Tubal and Peritoneal Cancers : Japan Clinical Oncology Group Study JCOG0602. Jpn J Clin Oncol 38 : 74─77, 2008